Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
Objective Mirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely active ulcerative colitis (UC). We studied mirikizumab’s impact on health-related quality of life (HRQoL).Design HRQoL was evaluated using t...
Main Authors: | Brian G Feagan, Toshifumi Hibi, Vipul Jairath, Nathan Morris, Bruce E Sands, Marla C Dubinsky, Vipin Arora, April N Naegeli, Trevor Lissoos, Mingyang Shan, Jay Tuttle, Noah Agada |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | BMJ Open Gastroenterology |
Online Access: | https://bmjopengastro.bmj.com/content/10/1/e001115.full |
Similar Items
-
Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission
by: Dubinsky, MC, et al.
Published: (2022) -
Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
by: Marla C. Dubinsky, et al.
Published: (2022-11-01) -
Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis
by: Dubinsky, MC, et al.
Published: (2022) -
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
by: Travis, S, et al.
Published: (2012) -
Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis
by: Taku Kobayashi, et al.
Published: (2023-04-01)